Most cited papers in Cancer Immunotherapy and Biomarkers
What are the most cited papers in Cancer Immunotherapy and Biomarkers?
The most cited paper in Cancer Immunotherapy and Biomarkers is "PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer" (Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al., 2016), with 30,915 citations. Next come "Improved Survival with Ipilimumab in Patients with Metastatic Melanoma" (15,337) and "Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review" (15,286).
Showing 50 of 100 papers. Every paper with more than 3,344 citations is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener et al. · Breast Care | 2016 | 30,915 |
| 2 | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma Frank Stephen Hodi et al. · New England Journal of Medicine | 5 Jun 2010 | 15,337 |
| 3 | Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review Rimda Wanchoo, Sabine Karam, Nupur N. Uppal et al. · American Journal of Nephrology | 2017 | 15,286 |
| 4 | The blockade of immune checkpoints in cancer immunotherapy Drew M. Pardoll · Nature reviews. Cancer | 22 Mar 2012 | 14,033 |
| 5 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer Suzanne Louise Topalian et al. · New England Journal of Medicine | 14 Jun 2012 | 12,842 |
| 6 | Immunity, Inflammation, and Cancer Sergei I. Grivennikov, Florian R. Greten, Michael Karin · Cell | Mar 2010 | 10,888 |
| 7 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer Martin Reck, Delvys Rodríguez‐Abreu, Andrew George Robinson et al. · New England Journal of Medicine | 9 Oct 2016 | 10,303 |
| 8 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency Dung Thi Le et al. · New England Journal of Medicine | 30 May 2015 | 9,595 |
| 9 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer H. Borghaei et al. · New England Journal of Medicine | 27 Sep 2015 | 9,557 |
| 10 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie Renee Brahmer et al. · New England Journal of Medicine | 31 May 2015 | 8,632 |
| 11 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin et al. · New England Journal of Medicine | 31 May 2015 | 8,266 |
| 12 | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie Renee Brahmer et al. · New England Journal of Medicine | 14 Jun 2012 | 8,100 |
| 13 | Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi et al. · Science | 12 Mar 2015 | 8,049 |
| 14 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation Paul B. Chapman et al. · New England Journal of Medicine | 5 Jun 2011 | 7,801 |
| 15 | Inflammation and cancer: back to Virchow? Frances R. Balkwill, Alberto Mantovani · The Lancet | Feb 2001 | 7,766 |
| 16 | Oncology Meets Immunology: The Cancer-Immunity Cycle Daniel S. Chen, Ira Mellman · Immunity | Jul 2013 | 7,122 |
| 17 | Cancer immunotherapy using checkpoint blockade Antoni Ribas, Jedd D. Wolchok · Science | 22 Mar 2018 | 6,951 |
| 18 | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade Dung Thi Le et al. · Science | 27 Jul 2017 | 6,813 |
| 19 | Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi et al. · New England Journal of Medicine | 16 Apr 2018 | 6,764 |
| 20 | PD-1 blockade induces responses by inhibiting adaptive immune resistance Paul C. Tumeh et al. · Nature | 25 Nov 2014 | 6,760 |
| 21 | TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells Taiwen Li, Jing‐Yu Fan, Binbin Wang et al. · Cancer Research | 31 Oct 2017 | 6,637 |
| 22 | Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo et al. · Science | 28 Sep 2006 | 6,620 |
| 23 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet | 19 Dec 2015 | 6,590 |
| 24 | Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion Robert D. Schreiber, Lloyd J. Old, Mark John Smyth · Science | 24 Mar 2011 | 6,561 |
| 25 | A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments] NL Harris, ES Jaffe, H Stein et al. · Blood | Sep 1994 | 6,356 |
| 26 | Understanding the tumor immune microenvironment (TIME) for effective therapy Mikhail Binnewies, Edward W. Roberts, Kelly Kersten et al. · Nature Medicine | 20 Apr 2018 | 6,338 |
| 27 | The Immune Landscape of Cancer Vésteinn Thórsson et al. · Immunity | Apr 2018 | 6,328 |
| 28 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer Edward B. Garon et al. · New England Journal of Medicine | 19 Apr 2015 | 6,312 |
| 29 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert John Motzer et al. · New England Journal of Medicine | 25 Sep 2015 | 5,972 |
| 30 | Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert et al. · New England Journal of Medicine | 19 Apr 2015 | 5,968 |
| 31 | TIMER2.0 for analysis of tumor-infiltrating immune cells Taiwen Li, Jingxin Fu, Zexian Zeng et al. · Nucleic Acids Research | 17 May 2020 | 5,803 |
| 32 | TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells Sanjeev Mariathasan et al. · Nature | Feb 2018 | 5,718 |
| 33 | Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response Peng Jiang, Shengqing Stan Gu, Deng Pan et al. · Nature Medicine | 13 Aug 2018 | 5,708 |
| 34 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer Ann Wargo et al. · Cell | Feb 2017 | 5,686 |
| 35 | Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors Bertrand Routy et al. · Science | 2 Nov 2017 | 5,679 |
| 36 | Elements of cancer immunity and the cancer–immune set point Daniel S. Chen, Ira Mellman · Nature | 2017 | 5,520 |
| 37 | Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade Pornpimol Charoentong, Francesca Finotello, Mihaela Angelova et al. · Cell Reports | 2017 | 5,483 |
| 38 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok et al. · New England Journal of Medicine | 11 Sep 2017 | 5,453 |
| 39 | Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq Itay Tirosh et al. · Science | 7 Apr 2016 | 5,440 |
| 40 | Nivolumab in Previously Untreated Melanoma without BRAF Mutation Caroline Robert et al. · New England Journal of Medicine | 16 Nov 2014 | 5,431 |
| 41 | PD-1 and Its Ligands in Tolerance and Immunity Mary E Keir, Manish J. Butte, Gordon James Freeman et al. · Annual Review of Immunology | 3 Jan 2008 | 5,426 |
| 42 | Cancer immunoediting: from immunosurveillance to tumor escape Gavin P. Dunn, Allen T. Bruce, Hiroaki Ikeda et al. · Nature Immunology | 29 Oct 2002 | 5,415 |
| 43 | Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Roy S. Herbst et al. · Nature | 25 Nov 2014 | 5,353 |
| 44 | Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation Gordon J. Freeman, Andrew J. Long, Yoshiko Iwai et al. · The Journal of Experimental Medicine | 2 Oct 2000 | 5,324 |
| 45 | A New Initiative on Precision Medicine Francis S. Collins, HAROLD E. VARMUS · New England Journal of Medicine | 30 Jan 2015 | 5,301 |
| 46 | Macrophage Diversity Enhances Tumor Progression and Metastasis Bin‐Zhi Qian, Jeffrey W. Pollard · Cell | Apr 2010 | 5,286 |
| 47 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Robert Louis Ferris et al. · New England Journal of Medicine | 9 Oct 2016 | 5,189 |
| 48 | Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion Haidong Dong, Scott Eric Strome, Diva R. Salomão et al. · Nature Medicine | 24 Jun 2002 | 5,107 |
| 49 | The immune contexture in human tumours: impact on clinical outcome Wolf H. Fridman, Franck Pagès, Catherine Sautès‐Fridman et al. · Nature reviews. Cancer | 15 Mar 2012 | 5,087 |
| 50 | The future of immune checkpoint therapy Padmanee Sharma, James Patrick Allison · Science | 2 Apr 2015 | 4,925 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.